Biotech & Life Sciences

The biotech technology stack is undergoing a generational shift. CRISPR gene editing has matured from a research tool to a therapeutic platform, with base editing (Beam Therapeutics), prime editing (Prime Medicine), and epigenetic editing expanding the precision and safety of genetic interventions. mRNA technology, validated by COVID vaccines, is being applied to cancer vaccines, rare diseases, and protein replacement therapies by companies like Moderna, BioNTech, and CureVac. AI and machine learning are transforming every stage of drug development: target identification (using multi-omic data), molecular design (generative chemistry), clinical trial optimization (synthetic control arms, adaptive designs), and manufacturing process optimization. Single-cell genomics and spatial transcriptomics are enabling researchers to understand disease at unprecedented resolution, revealing new drug targets and biomarkers. Protein engineering using directed evolution and computational design is creating novel biologics with properties not found in nature. Antibody-drug conjugates (ADCs) have emerged as one of the most commercially successful therapeutic modalities, combining the targeting specificity of antibodies with the potency of small molecule drugs.

Biotech applications span the full spectrum of human health. In oncology, CAR-T cell therapies (Kymriah, Yescarta) reprogram patients' immune cells to attack cancer, and next-generation approaches including allogeneic (off-the-shelf) CAR-T and bispecific antibodies are expanding access beyond specialized treatment centers. In rare diseases, gene therapies like Zolgensma (spinal muscular atrophy) and Casgevy (sickle cell disease, the first CRISPR therapy) are providing one-time curative treatments for conditions that previously had no effective therapy. In metabolic diseases, GLP-1 agonists (Ozempic, Mounjaro, Wegovy) have become the fastest-growing drug class in pharmaceutical history, treating both diabetes and obesity. In neuroscience, Lecanemab (Leqembi) represents the first disease-modifying Alzheimer's therapy, though its modest efficacy highlights how much further the field needs to go. In synthetic biology, companies like Ginkgo Bioworks and Zymergen are engineering microorganisms to produce chemicals, materials, and food ingredients that would otherwise come from petrochemical or agricultural sources. In diagnostics, liquid biopsy companies (Grail, Guardant Health) are making cancer detection possible through simple blood draws.

The global biotech and life sciences market exceeded $1.6 trillion in 2025, encompassing therapeutics development, diagnostics, genomics, synthetic biology, and the rapidly growing category of AI-driven drug discovery. Venture capital in biotech surpassed pre-pandemic levels in 2024, with early venture rounds reaching $15.5 billion and late-stage rounds bringing in $7.6 billion. The sector experienced a meaningful recovery through 2025, with Q3 2025 venture financing deal value reaching $3.1 billion, a 70.9% increase over Q2. The market is bifurcated: a handful of well-capitalized platform companies raising mega-rounds alongside a long tail of earlier-stage companies competing for a shrinking pool of seed and Series A capital. The intensifying GLP-1 market (projected to reach $150 billion by 2030), advancing AI applications in drug discovery, and the maturation of cell and gene therapy manufacturing are the primary market drivers pulling capital into the sector.